Adept Gdept Fda Guidance

Adessi, C. and Soto, C. (2002). Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9:963-978.

Agharkar, S., Lindenbaum, S., and Higuchi, T. (1976). Enhancement of solubility of drug salts by hydrophilic counterions: properties of organic salts of an antimalarial drug. J. Pharm. Sci. 65:747-749.

Ahr, G., Voith, B., and Kuhlmann, J. (2000). Guidances related to bioavailability and bioequivalence: European industry perspective. Eur. J. Drug Metab. Pharmacokinet. 25:25-27.

Amidon, G. L., Lennernas, H., Shah, V. P., and Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420.

Anderson, P. M. and Sorenson, M. A. (1994). Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet. 27:19-31.

Berridge, M. S., Lee, Z., and Heald, D. L. (2000). Regional distribution and kinetics of inhaled pharmaceuticals. Curr. Pharm. Des. 6:1631-1651.

Blume, H. H. and Schug, B. S. (1999). The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? Eur. J. Pharm. Sci. 9:117-121.

Chen, L. and Waxman, D. J. (2002). Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des. 8:1405-1416.

Chen, J., Jiang, X. G., Jiang, W. M., Gao, X. L., and Mei, N. (2005). Intranasal absorption of rizatriptan - in vivo pharmacokinetics and bioavailability study in humans. Pharmazie 60:39-41.

Curatolo, W. (1998). Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today 1:387-393.

Dannenfelser, R. M., He, H., Joshi, Y., Bateman, S., and Serajuddin, A. T. (2004). Development of clinical dosage forms for a poorly water soluble drug I: application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J. Pharm. Sci. 93:1165-1175.

Dressman, J. B., Amidon, G. L., Reppas, C., and Shah, V. P. (1998). Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15:11-22.

FDA (U.S. Food and Drug Administration) Guidance Documents for Industry, 1995, Rockville. Guidance for Industry. Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (November 1995); http://www.fda.gov/cder/guidance/cmc5.pdf.

FDA (U.S. Food and Drug Administration) Guidance for Industry, 2000, Rockville. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products -General Considerations (October 2000); http://www.fda.gov/cder/guidance/3615fnl.pdf.

FDA (U.S. Food and Drug Administration) Guidance for Industry, 2005, Rockville. The Biopharmaceutics Classification System (BCS) Guidance (June 2005); http://www.fda.gov/cder/OPS/BCS_guidance.htm.

Flynn, G. L. (1984). Solubility concepts and their applications to the formulation of pharmaceutical systems. Part I. Theoretical foundations. J. Parenter. Sci. Technol. 38:202-209.

Gennaro, A. R. (ed.). (1995). Remington: The Science and Practice of Pharmacy, 19th ed. Mack Publishing Co., Easton, PA.

Gibaldi, M. and Perrier, D. (1982). Pharmacokinetics, 2nd ed. Marcel Dekker Inc., New York.

Gu, C. H., Rao, D., Gandhi, R. B., Hilden, J., and Raghavan, K. (2005). Using a novel multi-compartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J. Pharm. Sci. 94:199-208.

Han, H. K. and Amidon, G. L. (2000). Targeted prodrug design to optimize drug delivery. AAPS PharmSci. (online). 2(1): article 6.

Hao, J. and Heng, P. W. (2003). Buccal delivery systems. Drug Dev. Ind. Pharm. 29:821-832.

Higuchi, T. (1958). Some physical chemical aspects of suspension formulation. J. Am. Pharm. Assoc. 47:657-660.

Higuchi, T. (1976). Pharmacy, pharmaceutics and modern drug delivery. Am. J. Hosp. Pharm. 33:795-800.

Higuchi, T., Szulczewski, D. H., and Yunker, M. (1956). Physical chemical properties and ultraviolet spectral characteristics of amyl nitrite. J. Am. Pharm. Assoc. 45:776-779.

Higuchi, W. I., Parrott, E. L., Wurster, D. E., and Higuchi, T. (1958). Investigation of drug release from solids. II. Theoretical and experimental study of influences of bases and buffers on rates of dissolution of acidic solids. J. Am. Pharm. Assoc. 47:376-383.

Higuchi, W. I., Lau, P. K., Higuchi, T., and Shell, J. W. (1963). Polymorphism and drug availability. Solubility relationships in the methylprednisolone system. J. Pharm. Sci. 52:150-153.

Hilgers, A. R., Smith, D. P., Biermacher, J. J., Day, J. S., Jensen, J. L., Sims, S. M., Adams, W. J., Friis, J. M., Palandra, J., Hosley, J. D., Shobe, E. M., and Burton, P. S. (2003). Predicting oral absorption of drugs: a case study with a novel class of antimicrobial agents. Pharm. Res. 20:1149-1155.

Ishii, K., Katayama, Y., Itai, S., Ito, Y., and Hayashi, H. (1995). A new pharmacokinetic model including in vivo dissolution and gastrointestinal transit parameters. Biol. Pharm. Bull. 18:882-886.

Johnson, K. C. and Swindell, A. C. (1996). Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 13:1795-1798.

Jung, M. (2001). Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy. Mini. Rev. Med. Chem. 1:399-407.

Kalgutkar, A. S., Vaz, A. D., Lame, M. E., Henne, K. R., Soglia, J., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C., Hendsch, Z. S., and Hop, C. E. (2005). Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 33:243-253.

Katsura, T. and Inui, K. (2003). Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab. Pharmacokinet. 18:1-15.

Kivisto, K. T., Niemi, M., and Fromm, M. F. (2004). Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam. Clin. Pharmacol. 18:621-626.

Kostenbauder, H. B. and Higuchi, T. (1957). A note on the water solubility of some N , N,-dialkylamides. J. Am. Pharm. Assoc. 46:205-206.

Kunta, J. R. and Sinko, P. J. (2004). Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab. 5:109-124.

Lee, H. J., Cooperwood, J. S., You, Z., and Ko, D. H. (2002). Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch. Pharm. Res. 25:111-136.

Lennernas, H. and Abrahamsson, B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 57:273-285.

Leslie, E. M., Deeley, R. G., and Cole, S. P. (2005). Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204:216-237.

Leuner, C. and Dressman, J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50:47-60.

Li, S., Wong, S., Sethia, S., Almoazen, H., Joshi, Y. M., and Serajuddin, A. T. (2005). Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm. Res. 22:628-635.

Lipka, E., Crison, J., and Amidon, G. L. (1996). Transmembrane transport of peptide type compounds: prospects for oral delivery. J. Control Release 39:121-129.

Lui, C. Y., Amidon, G. L., Berardi, R. R., Fleisher, D., Youngberg, C., and Dressman, J. B. (1986). Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 75:271-274.

Majumdar, S., Duvvuri, S., and Mitra, A. K. (2004). Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv. Drug Deliv. Rev. 56:1437-1452.

Merino,V., Freixas, J., del Val, B. M., Garrigues, T. M., Moreno, J., and Pla-Delfina, J. M. (1995). Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones. J. Pharm. Sci. 84:777-782.

Meyer, U. A. (1996). Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm. 24:449-459.

Morris, K. R. (1994). An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 105:209-217.

Nicolaides, E., Galia, E., Efthymiopoulos, C., Dressman, J. B., and Reppas, C. (1999). Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 16:1876-1882.

Parrott, N. and Lave, T. (2002). Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci. 17:51-61.

Pochopin, N. L., Charman, W. N., and Stella, V. J. (1994). Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. Drug Metab. Dispos. 22:770-775.

Porter, C. J., Kaukonen, A. M., Boyd, B. J., Edwards, G. A., and Charman, W. N. (2004). Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res. 21:1405-1412.

Prokai-Tatrai, K. and Prokai, L. (2003). Modifying peptide properties by prodrug design for enhanced transport into the CNS. Prog. Drug Res. 61:155-188.

Raw, A. S. and Yu, L. X. (ed.). (2004). Pharmaceutical solid polymorphism in drug development and regulation. Adv. Drug Deliv. Rev. 56:235-418.

Reinstein, J. A. and Higuchi, T. (1958). Examination of the physical chemical basis for the isoniazid-p-aminosalicylic acid combination. J. Am. Pharm. Assoc. 47:749-752.

Ritschel, W. A. (1996). Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin. Transplant. 10:364-373.

Rohatagi, S., Rhodes, G. R., and Chaikin, P. (1999). Absolute oral versus inhaled bioavail-ability: significance for inhaled drugs with special reference to inhaled glucocorticoids. J. Clin. Pharmacol. 39:661-663.

Rowland, M. and Tozer, T. N. (1989). Clinical Pharmacokinetics: Concepts and Applications, 2nd ed. Lea & Febiger, Philadelphia.

Sai, Y. (2005). Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab. Pharmacokinet. 20:91-99.

Shefter, E. and Higuchi, T. (1963). Dissolution behavior of crystalline solvated and nonsol-vated forms of some pharmaceuticals. J. Pharm. Sci. 52:781-791.

Shek, E., Higuchi, T., and Bodor, N. (1976). Improved delivery through biological membranes. 3. Delivery of N-methylpyridinium-2-carbaldoxime chloride through the blood-brain barrier in its dihydropyridine pro-drug form. J. Med. Chem. 19:113-117.

Shou, M., Lin, Y., Lu, P., Tang, C., Mei, Q., Cui, D., Tang, W., Ngui, J. S., Lin, C. C., Singh, R., Wong, B. K., Yergey, J. A., Lin, J. H., Pearson, P. G., Baillie, T. A., Rodrigues, A. D., and Rushmore, T. H. (2001). Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab. 2:17-36.

Shyu, W. C., Mayol, R. F., Pfeffer, M., Pittman, K. A., Gammans, R. E., and Barbhaiya, R. H. (1993). Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm. Drug Dispos. 14:371-379.

Singhal, D. and Curatolo, W. (2004). Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. 56:335-347.

Song, Y., Wang, Y., Thakur, R., Meidan, V. M., and Michniak, B. (2004). Mucosal drug delivery: membranes, methodologies, and applications. Crit. Rev. Ther. Drug Carrier Syst. 21:195-256.

Stella, V. J., Charman, W. N., and Naringrekar, V. H. (1985). Prodrugs. Do they have advantages in clinical practice? Drugs 29:455-473.

Sun, D., Yu, L. X., Hussain, M. A., Wall, D. A., Smith, R. L., and Amidon, G. L. (2004). In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr. Opin. Drug Discov. Devel. 7:75-85.

Varia, S. A. and Stella, V. J. (1984). Phenytoin prodrugs V: in vivo evaluation of some water-soluble phenytoin prodrugs in dogs. J. Pharm. Sci. 73:1080-1087.

Venkatesh, S. and Lipper, R. A. (2000). Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:145-154.

Verreck, G., Vandecruys, R., De Conde, V., Baert, L., Peeters, J., and Brewster, M. E. (2004). The use of three different solid dispersion formulations - melt extrusion, film-coated beads, and a glass thermoplastic system - to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J. Pharm. Sci. 93:1217-1228.

Woolf, H. B. (ed.). (1981). Webster's New Collegiate Dictionary, G. & C. Merriam Co., Springfield.

Yang, C., Tirucherai, G. S., and Mitra, A. K. (2001). Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther. 1:159-175.

Zhou, R., Moench, P., Heran, C., Lu, X., Mathias, N., Faria, T. N., Wall, D. A., Hussain, M. A., Smith, R. L., and Sun, D. (2005). pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharm. Res. 22:188-192.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment